40 results about "Hypotensive agents" patented technology

Analogs of the prostaglandin PGE1 are disclosed. These compounds exhibit uterotonic properties, enhancing the response to PGF2 alpha in isolated rat uteri. The compounds also exhibit other pharmacological properties, as inhibitors of gastric acid secretion, hypotensives, and bronchodilators. Processes for making the analogs, useful intermediates, and pharmaceutical preparations are also presented.

The invention relates to a lipid microsphere injection of butyrate clevidipine which is a rapid-effect hypotensive medicine and can be intravenously injected and a preparation method thereof. The lipid microsphere injection comprises butyrate clevidipine, oil for injection, an emulsifying agent, polyethylene glycol ester, medical additive and water for injection. The lipid microsphere injection can effectively control the medicine release at the same time of ensuring the curative effect and reduce the occurrence rate of adverse reactions.

The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.

A method whereby the blood pressure metabolism in an individual showing evidence of dysregulation is improved when that person receives an appropriate oral administration of (−)-hydroxycitric acid. The potassium salt of (−)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other derivatives of the acid. The regulation of blood pressure levels over any given period of time may be improved with a controlled release form of (−)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypotensive agent.

The present invention provides soy sauce that comprises significant amounts of peptides, and, in particular, hypotensive peptide Gly-Tyr and hypotensive peptide Ser-Tyr, exhibiting a high degree of angiotensin-I-converting enzyme-inhibitory activity and has hypotensive effects while containing no hypotensive agent. Target soy sauce is obtained by mixing soy sauce koji having protease activity of 20 to 300 U / g koji with an aqueous common salt solution and subjecting the mixture to heated digestion, followed by compression filtration. Target soy sauce with a good flavor is obtained by adding soy sauce lactic acid bacteria and soy sauce yeast cells to the moromi mash after heated digestion, and subjecting the resultant to fermentation and maturation, followed by compression filtration.

The invention discloses a preparation method of timolol maleate sustained release microspheres. The preparation method comprises the following steps: by adopting an oil-in-oil technology, preparing an internal phase from timolol maleate, modified montmorillonite, acrylic resin, tween and a plasticizer and preparing an external phase from vegetable oil and span; carrying out ultrasonic treatment on an obtained oil-in-oil emulsion; then, electromagnetically stirring to evaporate the internal phase to obtain the timolol maleate sustained release microspheres. The grain diameter of the timolol maleate sustained release microspheres can be controlled in a range of 10 mu m, so that the demand of eye-drops preparations is met. The medicine encapsulation rate reaches up to 80-99%, and the in vitro releasing time can be prolonged to 10-12 hours. The timolol maleate sustained release microspheres prepared by the method serving as an ocular hypotensive agent can reduce intraocular discomfort and reduce the medication frequency, so that the purpose of reducing intraocular pressure for a long time by one-time delivery is realized.

The present invention provides isoformes from a peptide family belonging to South American scorpion Tityus serrulatus that acts as hypotensive agents by potentiating Bradykinin and, therefore, can be used as anti-hypertensive drugs. A peptide was firstly isolated from Tityus serrulatus venom and showed a strong and long-lasted hypotensive activity when tested in rats. This peptide was first named TsHpt-I (Tityus serrulatus Hypotensin-I). Also, three more highly similar isoformes were identified and revealed a peptide family with very close primary structure. They were named TsHpt-II, TsHpt-III and TsHpt-IV.

A hypotensive agent comprising, as the active ingredient, a culture of a lactic acid bacterium which is produced by cultivating the lactic acid bacterium in a culture medium containing a microalga and the lactic acid bacterium.

The invention relates to the field of medicine preparation technologies, and aims to provide a method for preparing a medicine for treating hypertension from peony root, herba dendrobii officmalis andirbesartan. The method comprises the steps that after the peony root is subjected to levigation, alcohol extraction is conducted, residues after alcohol extraction are subjected to water extraction treatment, and concentrated extraction solutions are combined; the herba dendrobii officmalis is subjected to levigation, herba dendrobii officmalis powder and irbesartan powder are added into the combined extraction solution for even mixing; an accessory is added to prepare the medicine for treating hypertension. In the method, the curative effect of an alcohol and water extraction method extractof the peony root and the herba dendrobii officmalis powder on treating hypertension is outstanding, compared with conventional water extraction, the alcohol and water extraction method of the peony root has the advantages that component loss is reduced, thus the effectiveness is improved, and full use of the peony root can be promoted; through compatibility of the herba dendrobii officmalis withthe peony root, not only can the efficacy of decreasing the blood pressure be achieved, but also the good mid-term and long-term stable blood pressure can be obtained, and the physique with equilibrium between yin and yang is adjusted and recovered; by means of the traditional Chinese medicine and western medicine combined composition, under the condition of a small western medicine dosage, the curative effect close to that of the conventional dosage of a western hypotensive medicine can be achieved, and thus the application prospects are greatly expanded.

The invention relates to a controlled release formulation for Captopril, a hypotensive agent, and its preparing process, wherein the retardation release time of the slow release preparation can be as long as 4-6 hours, the effect duration of the preparation can be over 18 hours.

A hypotensive agent and food are disclosed, which contain Tricholoma matsutake, in particular Tricholoma matsutake of the FERM BP-7304 strain, and any of mycelia, broths, or fruit bodies (including spores) thereof, as they are, dried products thereof, or extracts thereof (e.g., a hot water extract or an alkaline solution extract). Methods of treating hypertension by the use of the hypotensive agent and food are also disclosed.

There are provided a method for selection of a substance which is capable of controlling activation of prorenin where an adjusting ability of the activation of prorenin by protein-protein interaction in a profragment region of prorenin as indicator is used; a prorenin activation controlling substance having a function of controlling the activation of prorenin based on protein-protein interaction by a profragment region of prorenin; and hypotensor, organ hypertrophy suppressor and arterial thickening suppressor containing the prorenin activation controlling substance as an effective ingredient.

Provided is an antihypertensive agent that is safe and has a mild effect.An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.

The invention discloses an application of a chondriokinesis inhibitor in preparation of medicines for preventing and treating hypertension, belonging to the technical field of biological medicines. The research proves that the chondriokinesis activity of blood vessels participates in vasotonia generation, and due to inhibition of chondriokinesis of blood vessels, vasoconstriction induced by phenylephrine and high potassium fluid can be obviously relaxed. According to a chondriokinesis inhibitor Mdivi-1 of which the structural formula is shown in a formula I, the vasoconstriction induced by phenylephrine and high potassium fluid can be obviously relaxed, so that the animal blood pressure is reduced. On the basis, the invention provides a method for screening novel hypotensive drugs and a novel application of the chondriokinesis inhibitor serving as a novel hypotensive drug. According to the application provided by the invention, a novel technical means is provided for prevention and treatment of hypertension. The structural formula is as shown in the specification.

The invention relates to the preparation field of a single configuration of a hypotensive drug (R)-cilnidipine, in particular to a preparation method of a hypotensive drug (R)-cilnidipine. The preparation method comprises the following steps: 1) adding ethyl cyano acetoacetate, m-nitrobenzaldehyde, 3-amino-2-methoxyethyl butenoate into isopropanol for a reflux reaction to obtain a racemized product; 2) adding the racemized product into an aqueous solution, adding lipase as a catalyst to stir for a catalytic reaction, and after reaction, acidifying and filtering a reaction liquid to obtain (R)-1,4-dihydrogen-2,6-dimethyl-4-(3-nitryl phenyl)-3,5-dipicolinic acid-5-(2-methoxyl ethyl); and 3) carrying out an esterification reaction with cinnamyl alcohol to obtain (R)-cilnidipine. The method provided by the invention obtains (R)-cilnidipine with high selectivity and high yield, and ee% reaches up to 99.7%.

The present invention provides a kind of reagent kit including reagent for detecting the polymorphic site genotype of natriuretic peptide gene of nucleic acid template. By means of PCR-RFLP method or Taqman method, the detection is fast, safe, convenient, sensitive and reliable. The detection can predict the hypotensive effect of angiotonin II receptor 1 agonist hypotensor and predict the functional state of the target organ of the primary hypertension patient, so that the medicine may be selected based on the individual difference to raise clinical treating efficiency and safety and lower the toxic side effect risk and treating cost.

Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is -(CH2)6-, cis -CH2CH=CH-(CH2)3-, or -CH2C=C-(CH2)3-, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is -(CH2)m-Ar-(CH2)o- wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 -CH2- may be replaced by S or O, and 1 -CH2-CH2- may be replaced by -CH=CH- or -C=C-; U1 and U2 are independently selected from -H, =O, -OH, -F, -Cl, and -CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.

A method and composition for treating a macular condition selected from the group consisting of macular degeneration or macular edema. A therapeutically effective amount of a carbonic anhydrase isoform IX inhibitor is administered to the patient to normalize intracellular pH of retinal pigment epithelial cells. The carbonic anhydrase isoform IX inhibitor can be administered alone or in combination with a therapeutically effective amount of an ocular hypotensive agent sufficient to improve visual function.

The object is to find a novel pharmacological activity of a compound capable of inhibiting an HDAC. The compound capable of inhibiting a histone deacetylase has an excellent ability of changing the cytomorphology of a trabeculara cell and / or an excellent ocular hypotensive activity, and is therefore useful as a prophylactic and / or therapeutic agent for a disease associated with aqueous humor circulation and / or ocular tension, particularly a prophylactic and / or therapeutic agent for glaucoma, ocular hypertension or the like.

The invention relates to the field of perfume, in particular to hypotensive pharmacological perfume, which is prepared from the following ingredients in parts by weight: 15 to 22 parts of rhizoma polygonati, 13 to 16 parts of spica prunellae, 14 to 17 parts of herba leonuri, 12 to 17 parts of herba plantaginis, 12-17 parts of herba siegesbeckiae, 25-35 parts of herba taxilli, 8-12 parts of apocynum venetum, 2-4 parts of flos chrysanthemi, 5-7 parts of flos sophorae, 4-6 parts of resveratrol, 8-10 parts of rosemary essential oil, 5-7 parts of lemon essential oil, 1-4 parts of sweet orange essential oil, 4-6 parts of neroli hydrolat and 3-6 parts of rose hydrolat. The hypotensive pharmacological perfume has the effect of lowering blood pressure.

One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient.

Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a LogD value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.]

The present invention provides a fimasartan compound. The Fimasartan (1) has a chemical name of 2-butyl-5-dimethylaminothiocarbamoylmethyl-6-methyl-3-[[2'-(1H) tetrazole-5-yl)biphenyl-4-yl-]methyl]pyrimidine-4(3H)-one, and is a novel angiotensin II receptor blocker antihypertensive drug. Preclinical studies and clinical trials show that the Fimasartan is safer than other ARB (angiotensin receptorblocker) drugs, and more effective in reducing diastolic blood pressure of hearts, and has good tolerance. The Fimasartan compound has characteristic peaks at 18.74, 21.10, and 24.00 in an X-ray powder diffraction spectrum.